Rgenix Reports Phase 1a/B Clinical Data Demonstrating Immune-Stimulatory Activity With RGX-104
Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today preliminary data from ...